Rivus Pharmaceuticals Inc., a US-based clinical-stage biopharmaceutical company, announced on Wednesday that it has named Dr Robert Schott as its new chief medical officer.

Schott has served as a senior vice president and head of development at Sangamo Therapeutics. He has also served at Eli Lilly for seven years as chief medical officer for Chorus, the autonomous early-phase drug development group inside Lilly..

Dr Schott said, 'I am delighted to be joining Rivus Pharmaceuticals, where the devoted founders and their team have made rapid progress in advancing HU6 into the clinic. This investigational therapeutic has the potential to address a number of obesity-associated diseases through a novel but well-characterised mechanism, which could address unmet medical needs in many patients with the metabolic consequences of obesity.'